About the PIC2

  ABOUT

      In pursuit of our mission to drive computational translational research for faster and more innovative discoveries, PIC2 stands as a genetically powered drug-target discovery engine. It, along with the resultant resource, accelerates translational breakthroughs, marking a significant paradigm shift from Covid-19 host genetic insights towards actionable translational applications.

      PIC2 encompasses two key components, featuring a genetics-led target prioritisation approach (known as PIT generating PIC2Target) and a crosstalk-based drug repurposing strategy (known as PID generating PIC2Drug). These two approaches collectively combat information overload and empower scientists to make swift decisions in selecting therapeutic candidates for further preclinical evaluations and, ultimately, clinical trials.

      To summarise, these two approaches culminate in the creation of two distinct indexes, collectively forming the comprehensive resource, namely PIC2 (see depicted below):
    • The PIT (the left panel) translates host genetic insights into the genetic target index (PIC2Target), achieved through the integration of multi-modal regulatory genomic datasets and high-quality protein interactions.
    • The PID (the right panel) excels in drug repurposing by leveraging genes that mediate crosstalk among molecular pathways, and when coupled with effect-by-removal analysis, in identifying the repurposed drug index (PIC2Drug).

  FUNDING

    National Natural Science Foundation of China (32170663)

    2022 - 2025


  PUBLICATIONS

    Priority index: database of genetic targets in immune-mediated disease

    Nucleic Acids Research 2022

    DOI: 10.1093/nar/gkab994

    From genome-wide association studies to rational drug target prioritisation in inflammatory arthritis

    Lancet Rheumatology 2020

    DOI: 10.1016/S2665-9913(19)30134-1

    Priority index for human genetics and drug discovery

    Nature Genetics 2019

    DOI: 10.1038/s41588-019-0460-5

    A genetics-led approach defines the drug target landscape of 30 immune-related traits

    Nature Genetics 2019

    DOI: 10.1038/s41588-019-0456-1